Acurx Pharmaceuticals, Inc.
ACXP
$4.08
$0.225.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.64% | -21.57% | 1.94% | 37.90% | 36.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.09% | -26.02% | -3.25% | 29.18% | 27.22% |
| Operating Income | 40.09% | 26.02% | 3.25% | -29.18% | -27.22% |
| Income Before Tax | 40.23% | 26.03% | 3.26% | -29.18% | -27.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.23% | 26.03% | 3.26% | -29.18% | -27.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.23% | 26.03% | 3.26% | -29.18% | -27.22% |
| EBIT | 40.09% | 26.02% | 3.25% | -29.18% | -27.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 53.29% | 40.03% | 22.87% | -3.13% | -1.93% |
| Normalized Basic EPS | 53.29% | 40.03% | 22.87% | -3.13% | -1.93% |
| EPS Diluted | 53.29% | 40.03% | 22.87% | -3.13% | -1.93% |
| Normalized Diluted EPS | 53.29% | 40.03% | 22.87% | -3.13% | -1.93% |
| Average Basic Shares Outstanding | 32.67% | 26.88% | 27.47% | 26.95% | 24.81% |
| Average Diluted Shares Outstanding | 32.67% | 26.88% | 27.47% | 26.95% | 24.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |